about
1st Joint European Conference on Therapeutic Targets and Medicinal Chemistry (TTMC 2015)A 3D-QSAR CoMSIA study on 3-azolylmethylindoles as anti-leishmanial agents.A safe and practical method for the preparation of 7α-thioether and thioester derivatives of spironolactone.Occurrence of the synthetic analgesic tramadol in an African medicinal plant.Screening of indeno[1,2-b]indoloquinones by MALDI-MS: a new set of potential CDC25 phosphatase inhibitors brought to light.2-Indolylmethylenebenzofuranones as first effective inhibitors of ABCC2.In Search of Small Molecule Inhibitors Targeting the Flexible CK2 Subunit Interface.Indenoindoles and cyclopentacarbazoles as bioactive compounds: synthesis and biological applications.Sleep Disorders and Therapeutic Management: A Survey in a French Population of Prisoners.Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells.Biologically active carbazole derivatives: focus on oxazinocarbazoles and related compounds.Discovery of 7-aryl-substituted (1,5-naphthyridin-4-yl)ureas as aurora kinase inhibitors.Toward selective CK2alpha and CK2alpha' inhibitors: Development of a novel whole-cell kinase assay by Autodisplay of catalytic CK2alpha'.Functional display of heterotetrameric human protein kinase CK2 on Escherichia coli: a novel tool for drug discoveryPhenolic indeno[1,2-b]indoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity.Development of Pharmacophore Model for Indeno[1,2-b]indoles as Human Protein Kinase CK2 Inhibitors and Database Mining.Crystal structure of 13-phenyl-2,3,4,13-tetra-hydro-1H-indazolo[1,2-b]phthalazine-1,6,11-trioneAn Updated View on an Emerging Target: Selected Papers from the 8th International Conference on Protein Kinase CK2.Design, synthesis, and in vitro antifungal activity of 1-[(4-substituted-benzyl)methylamino]-2-(2,4-difluorophenyl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ols.Design of new antifungal agents: synthesis and evaluation of 1-[(1H-indol-5-ylmethyl)amino]-2-phenyl-3-(1H-1,2,4-triazol-1-yl)propan-2-ols.Potential application of plant lipid transfer proteins for drug delivery.Synthesis and structure-activity relationships of 2-phenyl-1-[(pyridinyl- and piperidinylmethyl)amino]-3-(1H-1,2,4-triazol-1-yl)propan-2-ols as antifungal agents.Synthesis and antifungal activity of new 1-halogenobenzyl-3-imidazolylmethylindole derivatives.Synthesis and antileishmanial activity of 3-(alpha-azolylbenzyl)indoles.In vitro activity of a new antifungal azolyl-substituted indole against Aspergillus fumigatus.Preparation and pharmacological profile of 7-(alpha-azolylbenzyl)-1H-indoles and indolines as new aromatase inhibitors.1H and 13C NMR assignments of bioactive indeno[1,2-b]indole-10-one derivatives.2- and 3-[(aryl)(azolyl)methyl]indoles as potential non-steroidal aromatase inhibitors.Design, synthesis and evaluation of 3-(imidazol- 1-ylmethyl)indoles as antileishmanial agents. Part II.Synthesis of 6- or 4-functionalized indoles via a reductive cyclization approach and evaluation as aromatase inhibitors.Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2.Synthesis and biological evaluation of 5-[(aryl)(1H-imidazol-1-yl)methyl]-1H-indoles: potent and selective aromatase inhibitors.Synthesis and biological evaluation of 3-(azolylmethyl)-1H-indoles and 3-(alpha-azolylbenzyl)-1H-indoles as selective aromatase inhibitors.Three-dimensional model of cytochrome P450 human aromatase.Unexpected Binding Mode of a Potent Indeno[1,2-b]indole-Type Inhibitor of Protein Kinase CK2 Revealed by Complex Structures with the Catalytic Subunit CK2α and Its Paralog CK2α'.Enhancement of iodinin solubility by encapsulation into cyclodextrin nanoparticles.Self-Assembled Supramolecular Nanoparticles Improve the Cytotoxic Efficacy of CK2 Inhibitor THN7.Inhibition of Shiga toxin-converting bacteriophage development by novel antioxidant compounds.Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.Indeno[1,2-b]indole derivatives as a novel class of potent human protein kinase CK2 inhibitors.
P50
Q28551058-97AB5953-2F58-4126-B5AD-63DC8C7B7582Q33248615-0D8781C6-56A0-4F0E-8B58-A5077A709213Q34305963-D346C17F-FDED-455C-B8F1-4D708C4CA582Q34369467-DF6C016E-FC4D-4EBF-B174-E55E008DF110Q36065100-0DD690E7-1712-45B9-AB11-90933C43CD45Q36072088-D95F4DB3-627B-4293-BD99-A02341E1F14BQ37731316-0EAEBEAC-1256-4782-B240-7DE57991E8BCQ38148859-0DE3333D-5890-4A7B-B8B7-4AD76FFDBEF3Q38867514-A94CA1C4-94A7-4C75-BE2A-357DA991D4A7Q38975540-D045426A-BF6B-4C41-9D91-62B4B313EC02Q39008583-D6B8181C-2EB2-4D8C-96C3-2C54C7917F87Q39055807-FCB53E44-514C-450B-9FF5-8692A1A8A587Q40087188-4C4320AE-4EC9-44BD-92FE-668C4C3FD13EQ40876363-C98C2E30-DEEF-42D1-8F1F-FF827E6AB9ACQ41138386-D44CD315-1613-4A8A-B2FD-B68C72B40808Q42112541-DDD2BD8E-B310-44D6-B827-278CA1915D5BQ42250108-547EC5E6-068A-44DA-AA56-0DFB17D08C11Q42333696-1750DBBC-1B69-44FD-8336-C16E3049127DQ42747611-9C6672FC-12CA-4483-BA89-CC77AF71CD8EQ43275171-3DAE0D71-4F3D-4BD1-8BAF-EA8B683E34C3Q43755355-B6515761-DD01-47AB-A762-2C3B96435463Q44198658-FA444226-CD7A-4F70-9396-74B5F16BE870Q44320485-9EABE0CA-3C2B-4AA8-8D4A-F64E368205C0Q44395536-CE1B080D-D812-40D5-8D56-0269A7661CF1Q44395556-7F18E719-ADC7-429F-98B1-93301BF2A4F1Q44406418-A3A5EF34-A62D-4972-9A67-0FAF081BC554Q44682962-19C8ABE9-7DAA-417E-A624-8ECDA606079BQ45232715-20F7A2A2-C6B2-47E8-8E02-2A711B047421Q45953296-84B678E1-208E-4BF4-94B9-2EBDE6B33C38Q46473550-51700291-D2EE-468F-B81A-6C9B098D6EC1Q46577165-10422BBC-F1D8-40B3-8B33-E630CC590F61Q46869928-73D4A834-8017-4E6D-8055-46819D5C5F77Q46884372-55A782DC-933A-4378-810F-AC5D8C055D8FQ46891612-A4F3E92C-80EF-44CB-B793-2605B134F9FEQ47162634-00D7D781-7C3E-433F-A561-1C30BC2AA7CCQ47715430-FD384BB2-69DA-4B08-AA55-C75B186A5073Q48159258-D6666F0D-7DB1-4F8C-A6B5-1A62CFFA2E31Q52656625-A1713A52-08B6-4E56-A209-00180E2F941BQ54318298-0F02E64C-38B8-445E-A7D7-042961D5B0C9Q54341393-345C1936-7DA2-4AD4-B84B-A66E3349990A
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marc Le Borgne
@ast
Marc Le Borgne
@en
Marc Le Borgne
@es
Marc Le Borgne
@nl
Marc Le Borgne
@sl
type
label
Marc Le Borgne
@ast
Marc Le Borgne
@en
Marc Le Borgne
@es
Marc Le Borgne
@nl
Marc Le Borgne
@sl
altLabel
Borgne ML
@en
Le Borgne M
@en
prefLabel
Marc Le Borgne
@ast
Marc Le Borgne
@en
Marc Le Borgne
@es
Marc Le Borgne
@nl
Marc Le Borgne
@sl
P1053
H-1036-2014
P106
P1153
6701821871
P21
P31
P3762
P3829
P3835
marc-le-borgne2
P4450
marc-le-borgne
P496
0000-0003-1398-075X